Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne (galantamine)—is expected to be ...

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44 million, which includes ...

Alpha Cognition licenses Zunveyl to China Medical System for $44M, covering Asia (excl. Japan), Australia, and New Zealand. ALPHA-1062 shows promise in reducing neuroinflammation and ...

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects.

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025 ...

The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYL™ in Alzheimer’s Disease, further research and development of its pipeline product candidates ...

The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the ...

These hires mark significant milestones in building Alpha Cognition’s commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild ...